Presentations
- Long Acting Injectable PrEP in Women: Laboratory Analysis of HIV Infections in HPTN 084 (IAS 2021)
- Long Acting Injectable Cabotegravir is Safe and Effective in Preventing HIV Infection in Cisgender Women: Results from HPTN 084 (HIV R4P 2021)
- Long acting cabotegravir (CAB LA): Planning for Success Across Global at-risk Populations (AIDS 2020)
- Community Presentations for HPTN 083 Results, including HPTN 084 implications (May 2020)
